The Five Additional Peptides FDA Will Review Next

The July 2026 vote was not the end of FDA's peptide review. The agency has already announced a second Pharmacy Compounding Advisory Committee meeting, and the compounds on that agenda are different from the seven reviewed in July.

What is scheduled

When FDA published its April 16, 2026 Federal Register notice announcing the July meeting, it also announced that the PCAC would convene again before the end of February 2027 to review five additional peptides for the Section 503A Bulk Drug Substances List (FDA Law Blog, April 21, 2026).

The five substances named for that review are:

• GHK-Cu
• Melanotan II
• Cathelicidin (LL-37)
• Dihexa acetate
• Pegylated Mechano Growth Factor (PEG-MGF)

As with July, each is expected to be considered in both free base and acetate forms, and FDA has not published the specific indications under review (FDA Law Blog).

Where the July compounds stand now

Nothing has been finalized. The PCAC recommended six of seven peptides — BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax — and voted against emideltide. Those votes are recommendations and are not binding on the FDA (NCPA, July 31, 2026).

Two steps remain before anything changes in practice.

Formal approval. Secretary of Health and Human Services Robert F. Kennedy, Jr. will still need to formally approve the substances' addition to the 503A Bulks List (NCPA).

Rulemaking. FDA will publish a proposed rule describing which peptides it plans to add or not add, followed by a public comment period, followed by a final rule (GoodRx Health). Notice-and-comment rulemaking under standard timelines can take more than a year, and the 503A bulks list final rulemaking has not yet occurred for most substances (FDA Law Blog).

One procedural change did take effect. In parallel with the meeting announcement, FDA updated its 503A bulk substance categories to reflect that the peptides under consideration would be removed from Category 2 within seven calendar days (FDA Law Blog).

Why Category 2 matters

In September 2023, FDA placed 19 peptides — including all seven considered at the July 2026 meeting — in Category 2 under Section 503A, a designation indicating significant safety concerns in compounding (Health Affairs Forefront).

If a peptide is ultimately added to the 503A Bulks List, it is reclassified into Category 1, meaning compounding pharmacies can compound drugs with that peptide pursuant to a valid prescription without risk of an enforcement action. That is not the same as FDA approval of the peptide as a drug (Little Health Law Blog, August 11, 2026).

What this does not establish

A favorable PCAC vote does not establish that a peptide works for every promoted purpose, does not eliminate unanswered safety questions, and does not make products sold by online research-chemical vendors legitimate (Dr. Sobo, July 26, 2026).

Health Affairs characterized the July vote as narrow support arriving despite a lack of evidence of clinical benefit and substantial safety and quality concerns (Health Affairs Forefront).

Dates to watch

• Before end of February 2027 — second PCAC meeting on the five peptides above
• Unscheduled — HHS decision on the July recommendations
• Unscheduled — proposed rule, public comment period, final rule

This page will be updated as FDA acts.

Grey Wolf Research tracks vendor pricing and certificate of analysis data for research-use-only compounds. Nothing on this page is medical advice, and no compound discussed here is approved by the FDA for human use. Products listed on this site are sold by third parties for laboratory research only and are not for human consumption.